Ixempra (Breast Cancer) - Analysis and Forecasts to 2020

GlobalData, December 2011, Pages: 35

Ixempra (Breast Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Ixempra (Breast Cancer) – Analysis and Forecasts to 2020” provides Ixempra sales estimates for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US
- Analysis and review of Ixempra including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Ixempra including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2007-2020 for Ixempra in the US

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Ixempra, Breast Cancer, ixabepilone, Sales forecast,Mitotic Inhibitor, Phase III, Phase 3, Pipeline, Competitors to Xeloda, Taxol and Halaven, Bristol-Myer's squibb

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Breast Cancer Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Age and Gender
2.3.2 Genetic Inheritance
2.3.3 Hormone Replacement Therapy
2.3.4 Radiation
2.3.5 Obesity
2.3.6 Alcohol Consumption
2.3.7 Late Child Birth
2.3.8 Use of Birth Control Pills
2.4 GlobalData Report Guidance
3 Breast Cancer: Market Characterization
3.1 Breast Cancer Market
3.2 Breast Cancer Market Forecasts and CAGR
3.3 Drivers of Breast Cancer Market
3.3.1 Breast Cancer: Most Frequent Cancer in Women
3.3.2 Increasing Breast Cancer Incidence Rate
3.3.3 Decreasing Breast Cancer Mortality Rate
3.3.4 High Survival Rates of Breast Cancer
4 Staging of Breast Cancer: Introduction
4.1 Distribution of Patients by Stages
4.1.1 Stages
5 Predictive Biomarker in the Treatment of Breast Cancer
6 Treatment Options of Breast Cancer
6.1 Stage 0 Breast Cancer
6.2 Early Stage Breast Cancer (Excluding Stage 0)
6.3 Metastatic Breast Cancer (MBC)
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line
6.3.2 Cytotoxic Chemotherapy
6.3.3 Management of Patients with HER-2 Positive Patients
7 Ixempra (ixabepilone)
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies of Ixempra
7.3.1 Phase III Combination Therapy Trial
7.3.2 Phase III Monotherapy Trial
7.4 Factors Affecting Sales of Ixempra
7.4.1 Limited Treatment Options
7.4.2 High Relative Efficacy
7.4.3 New Therapeutic Agent
7.4.4 Lack of Presence in EU and Japan
7.5 Drug Evaluation
7.5.1 Drug Risk Benefit Score
7.5.2 Intensity of Competition
7.6 Sales forecast
7.6.1 Target patient Pool of Ixempra
7.6.2 Dosing
7.6.3 Market Penetration
7.6.4 Annual Cost of Therapy
7.6.5 Sales Projections of Ixempra
8 Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of Patients Approved to Take the Drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030
Table 2: Five-Year Relative Survival Rates, 2005, By Stages
Table 3: Efficacy of Ixempra in Combination with Capecitabine vs Capecitabine Alone
Table 4: Drug Risk Benefit Score of Ixempra in Third-line treatment of Breast Cancer
Table 5: Ixempra, Breast Cancer, The US, Sales Estimates ($m), 2007–2020

1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030
Figure 10: Broad Classification of Breast Cancer, By Type
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS
Figure 12: Classification of Invasive Breast Cancer, By Stages
Figure 13: Classification of Invasive Breast Cancer, By Treatment
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness
Figure 17: Treatment Options, DCIS Breast Cancer
Figure 18: Treatment Options, LCIS Breast Cancer
Figure 19: Classification of Stages I, II and IIIA
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer)
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer)
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer)
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer
Figure 27: Drug Model Diagram of Ixempra
Figure 28: Ixempra, Breast Cancer, The US, Sales Estimates ($m), 2007–2020
Figure 29: Patients Approved for the Drug

Customers who bought this item also bought

• Global Breast Cancer Drug Pipeline Capsule - 2012 Update
• Oncology Partnering Terms and Agreements
• Global Breast Cancer Epidemiology and Patient Flow Analysis - 2012
• Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012
• RNA Interference (RNAi) - Global Strategic Business Report
• Positioning of Current and Emerging Targeted Agents in Breast Cancer: Physician & Payer Perspective on Treatment and Reimbursement Decisions in Europe
• Nuclear Medicine - Global Strategic Business Report